Plant Monoclonal Antibody Discovery Platforms

We are committed to becoming your reliable assistant and partner in the field of plant protein

  1. Home
  2. Platforms
  3. Plant Antibody Platforms
  4. Plant Monoclonal Antibody Discovery Platforms
Platforms
Online Inquiry

Plant Monoclonal Antibody Discovery Platforms

Inquiry

CD BioSciences's plant monoclonal antibody (mAbs) discovery platforms contain the hybridoma technology platform, phage display platform, and single B-cell screening platform. We tailor appropriate strategies to clients' requirements, producing higher quantities of high-quality plant antibodies for downstream research.

With the development of mAbs technology and molecular biology, mAbs have essential applications in plant research, especially in the investigation of plant proteins, including protein expression, protein localization, protein interactions, characterization and quantification of plant constituents, purification of plant constituents, detection of plant diseases, and labeled antibodies.

Plant Monoclonal Antibody Discovery Platforms

Hybridoma technology platform

Hybridoma technology generates stringent monoclonal antibodies by generating immortalized hybridoma cell lines, then screening antigen-specific clones and further cycling subclones.

Roadmap for hybridoma technology.  Figure 1. Roadmap for hybridoma technology. (Saeed, A. F., et al., 2017)

Plant antibody phage display platform

We utilize genetic engineering technology to attach antibody genes to phage display them on the phage surface, and complete the screening of phage-displayed antibodies by binding to target proteins.

Schematic diagram of phage display process. Figure 2. Schematic diagram of phage display process. (Teixeira, D. & Gonzalez-Pajuelo, M., 2018)

Single B-cell sorting platform

In recent years, single B-cell antibody discovery technology has been an emerging mAbs preparation technology. It combines single-cell isolation and identification with PCR technology to form a mAbs in vitro screening and expression system.

Workflow summary of mAb discovery based on single B-cell sorting. Figure 3. Workflow summary of mAb discovery based on single B-cell sorting. (Carbonetti, S., et al., 2017)

Comparison of Plant mAbs Discovery Platforms

Platforms Advantages Limitations
Hybridoma technology
  • High antibody affinity.
  • Positive impact on exploitable by preserving the natural VH-VL pairing.
  • Cheap.
  • Low efficiency of cell fusion and high loss of diversity.
  • Limited to rodents.
  • Not adapted to antigens of low immunogenicity and/or toxicity.
Phage display
  • There are no breed restrictions.
  • Random VH-VL pairing to maximize diversity.
  • High-throughput screening recognizes multiple conjugates.
  • Accommodates antigens of low immunogenicity and/or toxicity.
  • Very fast.
  • No need for animals due to pre-made libraries.
  • Unnatural VH-VL pairings can negatively impact exploitability.
  • Potential bias due to phage particles.
  • Low/medium antibody affinity due to lack of immunization.
  • High-affinity antibodies are expensive and require custom immunobank construction.
Single B-cell sorting
  • High antibody affinity.
  • Preservation of natural VH-VL pairs.
  • High-throughput screening.
  • Ideal for discovering rare antibodies against challenging targets with maximum exploitability.
  • Not adapted to antigens of low immunogenicity or toxicity.

CD BioSciences is the premier plant antibody discovery partner, providing end-to-end plant mAb discovery solutions to biotech companies and research organizations of all sizes. If you have any questions, please feel free tocontact us!

References

  1. Saeed, A. F., et al. (2017). Antibody Engineering for Pursuing a Healthier Future. Frontiers in microbiology. 8, 495.
  2. Teixeira, D., & Gonzalez-Pajuelo, M. (2018). Phage Display Technology for Selection of Antibody Fragments. Biomedical Applications of Functionalized Nanomaterials. 67-88.
  3. Carbonetti, S., et al. (2017). A method for the isolation and characterization of functional murine monoclonal antibodies by single B cell cloning. Journal of Immunological Methods. 448, 66-73.

For research use only, not for clinical use.